Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice

Han, Changsu; Wang, Sheng Min; Lee, Soo Jung; Jun, Tae-Won; Pae, Chi Un

doi:10.4068/cmj.2015.51.2.66

Cited by 18 publications

(10 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along with multiple symptoms, this disorder is associated with recurrent thoughts of death or suicide 1,2. The prevalence of MDD differs among countries; the estimated lifetime prevalence of major depressive episodes was 1.5% in Taiwan, 7% in Korea, 19.0% in Lebanon, 9.2% in Germany, and 9.0% in Chile 3. The global prevalence of major depressive disorder is generally estimated to be between 3% and 6% 4.…”

Section: Introductionmentioning

confidence: 99%

<p>The Effect of Eye Movement Desensitization and Reprocessing (EMDR) on the severity of suicidal thoughts in patients with major depressive disorder: a randomized controlled trial</p>

Fereidouni¹,

Behnammoghadam²,

Jahanfar³

et al. 2019

NDT

View full text Add to dashboard Cite

ObjectiveDepression is a major risk factor for suicide and more than 90% of people who attempt suicide suffer from depression. The present study aimed to investigate the effect of eye movement desensitization and reprocessing (EMDR) therapy on the severity of suicidal thoughts in patients with major depressive disorder.Study designRandomized Clinical Trial.MethodsThis clinical trial was performed on 70 people with major depressive disorder who exhibited suicidal thoughts. The patients were selected via convenience sampling and were randomly divided into control (n=35) and experimental (n=35) groups. EMDR was performed individually in the experimental group for 45–90 min, 3 days per week, on alternate days, for 3 weeks (9 sessions in total), whereas the controls group received routine treatment without intervention. Both groups completed the Beck Scale for Suicide Ideation (BSSI) at pre- and post-test. The obtained data were analyzed with descriptive and inferential statistics using SPSS 22 (α=0.05).ResultsMean BSSI score for the experimental group was reduced significantly at post-test (11.11±4.15) compared to pre-test (26.48±5.74) (p<0.001). Although the control group’s mean BSSI score was also reduced at post-test (24.93±4.42) compared to pre-test (26.68±5.05), this difference was not statistically significant (p>0.05).ConclusionEMDR therapy has been shown in this study to reduce the severity of suicidal feelings. Therefore, it can be recommended as an alternative treatment method for reducing the severity of suicidal thoughts in patients with major depressive disorder.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>The Effect of Eye Movement Desensitization and Reprocessing (EMDR) on the severity of suicidal thoughts in patients with major depressive disorder: a randomized controlled trial</p>

Fereidouni¹,

Behnammoghadam²,

Jahanfar³

et al. 2019

NDT

View full text Add to dashboard Cite

show abstract

“…Since January 2013, two more RPCTs studying the efficacy of aripiprazole adjunctive use in the treatment of MDD were published. 26 The first study, The Aripiprazole Depression Multicenter Efficacy (ADMIRE) study, was designed to evaluate the efficacy and safety of aripiprazole augmentation in Japanese patients with MDD. 27 Subjects with an inadequate response to 8 weeks of ADT were randomized to receive placebo augmentation, fixed dose aripiprazole, or flexible dose aripiprazole for 6 weeks.…”

Section: The Current Market Statusmentioning

confidence: 99%

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

et al. 2016

Self Cite

View full text Add to dashboard Cite

Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.

show abstract

“…Table 4 Antidepressants and antipsychotics combinations with highest combined scores Among the nominated drug combinations, Aripiprazole is the only SGAs and is also the most recommended treatment options for AD+P. As a matter of fact, the combination of Aripiprazole and Sertraline has already been tested in clinical trials and showed superior efficacy in treating major depressive disorders (MDD) with no reports of safety concerns 54 . However, none of these drug pairs have been tested for AD+P in clinical trials.…”

Section: Systems Pharmacology Studies Provided Possible Explanations ...mentioning

confidence: 99%

Combination of Antidepressants and Antipsychotics as A Novel Treatment Option for Psychosis in Alzheimer’s Disease

Fan

Zeng

Ding

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Psychotic symptoms are reported as one of the most common complications of Alzheimer's disease (AD), affecting approximately half of AD patients, in whom they are associated with more rapid deterioration and increased mortality. Empiric treatments, namely first and second-generation antipsychotics, confer modest efficacy in AD patients with psychosis (AD+P) and themselves increase mortality. A recent genome-wide meta-analysis and early clinical trials suggest the use and beneficial effects of antidepressants among AD+P patients. This motivates our rationale for exploring their potential as a novel combination therapy option amongst these patients. Methods: We included University of Pittsburgh Medical Center (UPMC) electronic medical records (EMRs) of 10,260 AD patients from January 2004 and October 2019 in our study. Survival analysis was performed to assess the effects of the combination of antipsychotics and antidepressants on the mortality of these patients. To provide more valuable insights on the hidden mechanisms of the combinatorial therapy, a protein-protein interaction (PPI) network representing AD+P was built, and network analysis methods were used to quantify the efficacy of these drugs on AD+P. An indicator score combining the measurements on the separation between drugs and the proximity between the drugs and AD+P was used to measure the effect of an antipsychotic-antidepressant drug pair against AD+P. Results: Our survival analyses replicated that antipsychotic usage is strongly associated with increased mortality in AD patients while the co-administration of antidepressants with antipsychotics showed a significant beneficial effect in reducing mortality. Our network analysis showed that the targets of antipsychotics and antidepressants are well-separated, and antipsychotics and antidepressants have similar proximity scores to AD+P. Eight drug pairs, including some popular recommendations like Aripiprazole/Sertraline and other pairs not reported previously like Iloperidone/Maprotiline showed higher than average indicator scores which suggest their potential in treating AD+P via strong synergetic effects as seen in our study. Conclusion: Our proposed combinations of antipsychotics and antidepressants therapy showed a strong superiority over current antipsychotics treatment for AD+P. The observed beneficial effects can be further strengthened by optimizing drug-pair selection based on our systems pharmacology analysis.

show abstract

Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice

Cited by 18 publications

References 120 publications

<p>The Effect of Eye Movement Desensitization and Reprocessing (EMDR) on the severity of suicidal thoughts in patients with major depressive disorder: a randomized controlled trial</p>

<p>The Effect of Eye Movement Desensitization and Reprocessing (EMDR) on the severity of suicidal thoughts in patients with major depressive disorder: a randomized controlled trial</p>

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

Combination of Antidepressants and Antipsychotics as A Novel Treatment Option for Psychosis in Alzheimer’s Disease

Contact Info

Product

Resources

About